In conclusion, we generated a HER3-targeting affibody-based drug conjugate, ZHER3-ABD-mcDM1, and extensively investigated its in vitro properties as well as determined its biodistribution in tumor-bearing mice. Here, ERBB3 is linked to neoplasm.